In a report issued on May 17, Raju Prasad from William Blair maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report). The company's shares closed last Monday at $10.84, close to its 52-week low of $7.57. According to TipRanks.com, Prasad has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -9.1% and a 35.5% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Crispr Therapeutics AG, and Allogene Therapeutics. Currently, the analyst consensus on Rocket Pharmaceuticals is a Strong Buy with an average price target of $64.40, a 495.7% upside from current levels.
https://www.tipranks.com/news/blurbs/william-blair-thinks-rocket-pharmaceuticals-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Jun 2022 to Jul 2022 Click Here for more Rocket Pharmaceuticals Charts.
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Jul 2021 to Jul 2022 Click Here for more Rocket Pharmaceuticals Charts.